Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Generalized anxiety disorder
17 evidence topics · 18 sources
United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022
United States diagnosed prevalence: Komodo Healthcare Map claims, adults, 2020 to 2023
“Projected annual prevalence increased from 5.4% in 2020–6.6% in 2023, with a 3-year prevalence of 10.3% over the 2021–2023 period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, more than one in ten adults met criteria for GAD over a three-year period, exceeding lifetime prevalence estimates from prior general population studies, which have ranged from approximately 5% to almost 8%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When this exclusion criterion was removed, the estimated one-year prevalence of GAD in 2023 increased from 6.6% in the base case to 7.2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Demographic analyses across each 1-year time period reveal that females appeared in GAD claims data at more than twice the rate of males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States past-year and lifetime prevalence: NCS-R, adults, 2001 to 2003
United States 12-month prevalence and severity: NCS-R, adults (n=9282)
| Generalized anxiety disorder, 12-month | Total, % (se) | Serious, % (se) | Moderate, % (se) | Mild, % (se) |
|---|---|---|---|---|
| NCS-R | “3.1 (0.2)”View highlighted excerpt for this quote | “32.3 (2.9)”View highlighted excerpt for this quote | “44.6 (4.0)”View highlighted excerpt for this quote | “23.1 (2.9)”View highlighted excerpt for this quote |
United States lifetime prevalence and lifetime morbid risk: NCS-R and NCS-A, ages 13 and older
“The LMR/12‐month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post‐traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The less common anxiety disorders include GAD (4.3%), panic disorder with or without agoraphobia (PD; 3.8%), agoraphobia with or without panic disorder (2.5%), and OCD (2.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These discrepancies might reflect the fact that GAD has a chronic‐episodic course reflected in intermediate prevalence ratios for all three age groups (roughly 35–50% of lifetime cases in episode in the 12 months before interview)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States 12-month and lifetime prevalence: NESARC, adults
United States adolescent lifetime prevalence: NCS-A, ages 13 to 18, 2001 to 2004
United States primary care prevalence: 15 clinics, 2004 to 2005
“15 U.S. primary care clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cross-national prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, 26 countries, 2001 to 2012
“Across all surveys, the combined lifetime prevalence of GAD was 3.7%, 12-month prevalence was 1.8%, and 30-day prevalence was 0.8% (Table 1). Lifetime prevalence estimates varied widely across countries, ranging from less than 1% of the populations of Nigeria and Shenzhen, China, to approximately 8% of the populations of Australia, New Zealand, and the United States. Prevalence increased with economic development: lifetime estimates (SE) were lowest in low-income (1.6% [0.1%]), moderate in middle-income (2.8% [0.1%]), and highest in high-income (5.0% [0.1%]) countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, US survey (n=9282)
| Country | Lifetime prevalence, No. (%) [SE] | 12-mo prevalence, No. (%) [SE] | 30-d prevalence, No. (%) [SE] | 12-mo prevalence among lifetime cases, No. (%) [SE] |
|---|---|---|---|---|
| United States | “752 (7.8) [0.3]”View highlighted excerpt for this quote | “394 (4.0) [0.2]”View highlighted excerpt for this quote | “157 (1.6) [0.2]”View highlighted excerpt for this quote | “394 (52.1) [1.8]”View highlighted excerpt for this quote |
Sponsor-stated number of United States adults with generalized anxiety disorder
Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019
Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019 and 2022
“During 2022, about one in five adults age 18 and older experienced any symptoms of anxiety (18.2%) or symptoms of depression (21.4%) in the past 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A significant increase was seen in the percentage of adults with anxiety symptoms (from 15.6% to 18.2%, respectively) and depression symptoms (from 18.5% to 21.4%, respectively) between 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positive GAD-7 screen, score of 10 or more (symptoms, not diagnosis): CLIMB cohort, United States adults, 2020 to 2022
“Using a longitudinal, nationally representative study of US adults, we used generalized estimating equations to estimate the burden of positive screen for GAD (GAD-7 score ≥ 10) over time. The final sample included 1270 adults at least 18 years old who completed the COVID-19 and Life Stressors Impact on Mental Health and Well-being (CLIMB) Study, with data collected in spring 2020, 2021, and 2022. The national prevalence of positive screen for GAD decreased from 24.4% in 2020 to 21.3% in 2022 (P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported past-month nervousness (single item, not diagnosis): NSDUH, United States adults, 2008 to 2018
“This variable was assessed with the item” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“how often did you feel nervous during the past 30 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anxiety increased from 5.12% in 2008 to 6.68% in 2018 (p < 0.0001) among adult Americans. Stratification by age revealed the most notable increase from 7.97% to 14.66% among respondents 18–25 years old (p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
“The accumulated anxiety disorder patients worldwide increased from 194.92 (95% UI: 165.10, 231.23) million in 1990 to 301.39 (95% UI: 252.63, 356.00) million in 2019, and kept a stable ASPR with around 37.8 (95% UI: 31.94, 44.77) per 1000 population during the period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote